1.50
4.90%
+0.07
Connect Biopharma Holdings Ltd ADR 주식(CNTB)의 최신 뉴스
Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma
GlobeNewswire Inc.
Connect Biopharma Reports Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire Inc.
Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors
GlobeNewswire Inc.
Are Medical Stocks Lagging Bausch Health (BHC) This Year?
Zacks Investment Research
Why Icosavax Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
Benzinga
Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma
GlobeNewswire Inc.
Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023
GlobeNewswire Inc.
Is Connect Biopharma Holdings (CNTB) Stock Outpacing Its Medical Peers This Year?
Zacks Investment Research
Why Urban Outfitters Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Why Guess? Shares Are Trading Lower By Around 15%; Here Are 20 Stocks Moving Premarket
Benzinga
Why Symbotic Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
Benzinga
Connect Biopharma and Simcere Announce Exclusive Licensing and Collaboration Agreement in Greater China
GlobeNewswire Inc.
Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis
GlobeNewswire Inc.
Connect Biopharma to Announce Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis on November 21, 2023
GlobeNewswire Inc.
자본화:
|
볼륨(24시간):